{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:08:21Z","timestamp":1784023701408,"version":"3.55.0"},"reference-count":81,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Unfractionated heparin (UFH) has long been an anticoagulant of choice. Despite the increasing use of low molecular weight heparin derivatives and more recently direct oral anticoagulants, UFH is still prescribed to prevent or treat thrombosis in specific populations at high risk of thrombosis or bleeding, including patients with severe renal impairment, critically ill patients, or those undergoing cardiac catheterization\/surgery. Due to its narrow therapeutic index, with a risk of hemorrhage in case of overdosing and a risk of thrombosis in case of underdosing, monitoring its anticoagulant activity is considered standard of care even though scientific data remains limited. Despite being used for decades, some unanswered questions remain, particularly regarding the biological monitoring of its efficacy. Which assay can be used? In practice, the most widely used tests are plasma\u2010based, such as the aPTT, a clotting assay, or the anti\u2010Xa activity, a chromogenic substrate\u2010based assay, whereas whole blood tests such as the ACT are limited to specific situation such as extracorporeal circulation. Which therapeutic ranges should be used? An aPTT prolongation of 1.5\u20132.5\u2009\u00d7\u2009control, or an anti\u2010Xa activity of 0.30\u20130.70\u2009IU\/mL, corresponding to 0.2\u20130.4\u2009U\/mL by protamine titration, ranges are commonly used, despite limited evidence\u2010based data. Furthermore, these assays are not standardized due to some degree of heterogeneity in the sensitivity of reagents to UFH. Moreover, some pre\u2010analytical questions remain, particularly regarding the collection tube to be used for example, citrate or CTAD anticoagulant solution, full\u2010 or partial\u2010draw (half\u2010filled) tubes, and the maximum time between collection and analysis.<\/jats:p>","DOI":"10.1111\/ijlh.70195","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:54:58Z","timestamp":1784022898000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Laboratory Monitoring Unfractionated Heparin Treatments: Unanswered Issues"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8610-8738","authenticated-orcid":false,"given":"Pierre","family":"Toulon","sequence":"first","affiliation":[{"name":"Hematology Department Universit\u00e9 C\u00f4te d'Azur, Nice University Hospital  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"1","key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and Low\u2010Molecular\u2010Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. The Sixth (2000) ACCP Guidelines for Antithrombotic Therapy for Prevention and Treatment of Thrombosis","volume":"119","author":"Hirsh J.","year":"2001","journal-title":"Chest"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/ajplegacy.1916.41.2.250","article-title":"The Thromboplastic Action of Cephalin","volume":"41","author":"McLean J.","year":"1916","journal-title":"American Journal of Physiology"},{"key":"e_1_2_8_4_1","first-page":"319","article-title":"Heparin and Post\u2010Operative Thrombosis","volume":"82","author":"Crafoord C.","year":"1939","journal-title":"Acta Chirurgica Scandinavica"},{"key":"e_1_2_8_5_1","first-page":"229","volume-title":"Heparin. Chemical and Biological Properties, Clinical Applications","author":"Bj\u00f6rk I.","year":"1989"},{"issue":"1","key":"e_1_2_8_6_1","first-page":"81","article-title":"Heparin to Pentasaccharide and Beyond: The End Is Not in Sight","volume":"30","author":"Messmore H. L.","year":"2004","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"e_1_2_8_7_1","first-page":"364","volume-title":"Heparin. Clinical and Biological Properties, Clinical Applications","author":"Lane D. A.","year":"1989"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0038-1649639","article-title":"Comparison of the Non\u2010Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins","volume":"70","author":"Young E.","year":"1993","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1055\/s-0040-1715460","article-title":"The Anticoagulant and Nonanticoagulant Properties of Heparin","volume":"120","author":"Beurskens D. M. H.","year":"2020","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44446\u2010025\u201000022\u20106"},{"issue":"2","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Garcia D. A.","year":"2012","journal-title":"Chest"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/jth.14898","article-title":"Heparin \u2013 An Old Drug With Multiple Potential Targets in Covid\u201019 Therapy","volume":"18","author":"Lindahl U.","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"e_1_2_8_13_1","unstructured":"\u201cFortune Business Insights Pvt. Ltd. Maharashtra India \u201daccessed February 24 2025 https:\/\/www.fortunebusinessinsights.com\/methodology\/heparin\u2010market\u2010104447."},{"key":"e_1_2_8_14_1","first-page":"1","volume-title":"CLSI Document H21\u2010ed6","author":"Winkler A. M.","year":"2024"},{"key":"e_1_2_8_15_1","first-page":"385","article-title":"Monitoring Heparin Therapy With the Activated Partial Thromboplastin Time","volume":"104","author":"Stuart R. K.","year":"1971","journal-title":"Canadian Medical Association Journal"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/ajcp\/59.4.581","article-title":"Comparison of Activated Partial Thromboplastin Reagents","volume":"59","author":"Sibley C.","year":"1973","journal-title":"American Journal of Clinical Pathology"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1600-0609.1979.tb00440.x","article-title":"The Varied Sensitivity of Partial Thromboplastin and Prothrombin Time Reagents in the Demonstration of the Lupus\u2010Like Anticoagulant","volume":"22","author":"Mannucci P. M.","year":"1979","journal-title":"Scandinavian Journal of Haematology"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2007.05.006","article-title":"Detection of Shortened Activated Partial Thromboplastin Times: An Evaluation of Different Commercial Reagents","volume":"121","author":"Ten Boekel E.","year":"2007","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ijlh.12499","article-title":"In Vitro Sensitivity of Different Activated Partial Thromboplastin Time Reagents to Mild Clotting Factor Deficiencies","volume":"38","author":"Toulon P.","year":"2016","journal-title":"International Journal of Laboratory Hematology"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ajcp\/71.1.22","article-title":"Activated Partial Thromboplastin Time and Minor Coagulopathies","volume":"71","author":"Hathaway W. E.","year":"1979","journal-title":"American Journal of Clinical Pathology"},{"issue":"4","key":"e_1_2_8_21_1","first-page":"530","article-title":"Laboratory Monitoring of Heparin. Effect of Reagents and Instruments on the Activated Partial Thromboplastin Time","volume":"76","author":"Brandt J. T.","year":"1981","journal-title":"American Journal of Clinical Pathology"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jcp.49.1.10","article-title":"Wide Variability in the Sensitivity of APTT Reagents for Monitoring of Heparin Dosage","volume":"49","author":"Kitchen S.","year":"1996","journal-title":"Journal of Clinical Pathology"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-0037-1615147","article-title":"Monitoring Heparin Therapy Using Activated Partial Thromboplastin Time\u2013Results of a Multicenter Trial Establishing the Therapeutic Range for SILIMAT, a Reagent With High Sensitivity to Heparin","volume":"80","author":"Toulon P.","year":"1998","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2011.11.016","article-title":"Monitoring Unfractionated Heparin With APTT: A French Collaborative Study Comparing Sensitivity to Heparin of 15 APTT Reagents","volume":"129","author":"AGEPS Hemostasis Group","year":"2012","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/jth.15264","article-title":"APTT Therapeutic Range for Monitoring Unfractionated Heparin Therapy. Significant Impact of the Anti\u2010Xa Reagent Used for Correlation","volume":"19","author":"Toulon P.","year":"2021","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1751-553X.2012.01445.x","article-title":"The Effect of Instrumentation and Laboratory Site on the Accuracy of the APTT\u2010Based Heparin Therapeutic Range","volume":"34","author":"Marlar R. A.","year":"2012","journal-title":"International Journal of Laboratory Hematology"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtha.2025.02.012","article-title":"Results of an International Survey on the Management of Therapeutic Intensity Unfractionated Heparin: Communication From the SSCs of the ISTH","volume":"23","author":"Gouin\u2010Thibault I.","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1055\/s-2007-1004365","article-title":"Amidolytic Antifactor Xa Assays in the Laboratory Evaluation of Heparin and Low Molecular Weight Fractions","volume":"11","author":"Walenga J. M.","year":"1985","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00001721-200011020-00004","article-title":"Monitoring Unfractionated Heparin Therapy: Relationship Between Eight Anti\u2010Xa Assays and a Protamine Titration Assay","volume":"11","author":"Kitchen S.","year":"2000","journal-title":"Blood Coagulation & Fibrinolysis"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1111\/jth.14969","article-title":"Monitoring Unfractionated Heparin Therapy: Lack of Standardization of Anti\u2010Xa Activity Reagents","volume":"18","author":"Smahi M.","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"e_1_2_8_31_1","first-page":"17","article-title":"Safety Issues in Heparin and Protamine Administration for Extracorporeal Circulation","volume":"12","author":"Jobes D. R.","year":"1998","journal-title":"Journal of Cardiothoracic and Vascular Anesthesia"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1177\/17085381241283519","article-title":"Systematic Review of Clinical Guidelines and Consensus Statements Concerning Heparin and Protamine Dosing and Monitoring of Anticoagulation Levels for Non\u2010Cardiac Arterial Procedures","volume":"33","author":"Roosendaal L. C.","year":"2025","journal-title":"Vascular"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cvr\/cvag043","article-title":"Anticoagulants Beyond Coagulation: A Narrative Review of Cardiovascular Effects","volume":"122","author":"Aarts A.","year":"2026","journal-title":"Cardiovascular Research"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.CIR.12.4.553","article-title":"Studies in Intravascular Coagulation. IV. The Effect of Heparin and Dicumarol on Serum\u2010Induced Venous Thrombosis","author":"Wessler S.","year":"1955","journal-title":"Circulation"},{"key":"e_1_2_8_35_1","first-page":"320","article-title":"Control of Heparin Therapy. Sensitivity of the Activated Partial Thromboplastin Time for Monitoring the Antithrombotic Effect of Heparin","volume":"73","author":"Zucker S.","year":"1969","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jama.1967.03130030027006","article-title":"Control of Heparin Therapy With Activated Partial Thromboplastin Times","volume":"201","author":"Spector I.","year":"1967","journal-title":"JAMA"},{"key":"e_1_2_8_37_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A Prospective Study of the Value of Monitoring Heparin Treatment With the Activated Partial Thromboplastin Time","volume":"287","author":"Basu D.","year":"1972","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5858\/arpa.2011-0516-OA","article-title":"The Optimum Number and Types of Plasma Samples Necessary for an Accurate Activated Partial Thromboplastin Time\u2010Based Heparin Therapeutic Range","volume":"137","author":"Marlar R. A.","year":"2013","journal-title":"Archives of Pathology & Laboratory Medicine"},{"key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/bjh.19729","article-title":"Measurement of Heparin, Direct Oral Anti\u2010Coagulants and Other Non\u2010Coumarin Anti\u2010Coagulants and Their Effects on Haemostasis Assays: A British Society for Haematology Guideline","volume":"205","author":"Baker P.","year":"2024","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1309\/AJCP60ZGXCJKRMJO","article-title":"Inaccuracy of a \u201cSpiked Curve\u201d for Monitoring Unfractionated Heparin Therapy","volume":"135","author":"Gausman J. N.","year":"2011","journal-title":"American Journal of Clinical Pathology"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/jth.13555","article-title":"A Century of Heparin: Past, Present and Future","volume":"14","author":"Hemker H. C.","year":"2016","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"e_1_2_8_42_1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa Levels Versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin","volume":"32","author":"Vandiver J. W.","year":"2012","journal-title":"Pharmacotherapy"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1345\/aph.1Q161","article-title":"Activated Partial Thromboplastin Time Versus Antifactor Xa Heparin Assay in Monitoring Unfractionated Heparin by Continuous Intravenous Infusion","volume":"45","author":"Guervil D. J.","year":"2011","journal-title":"Annals of Pharmacotherapy"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/1076029617741363","article-title":"Performance of Anti\u2010Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms","volume":"24","author":"Whitman\u2010Purves E.","year":"2018","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-119-2-199307150-00002","article-title":"Establishing a Therapeutic Range for Heparin Therapy","volume":"119","author":"Brill\u2010Edwards P.","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"e_1_2_8_46_1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1055\/s-0038-1646008","article-title":"Modification of an Amidolytic Heparin Assay to Express Protein\u2010Bound Heparin and to Correct for the Effect of Antithrombin III Concentration","volume":"58","author":"Lyon S. G.","year":"1987","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_47_1","article-title":"Optimization of Heparin Monitoring With Anti\u2010FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity","volume":"9","author":"Amiral J.","year":"2021","journal-title":"Biomedicine"},{"key":"e_1_2_8_48_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102257","article-title":"Reassessment of Dextran Sulfate in Anti\u2010Xa Assay for UFH Laboratory Monitoring","volume":"7","author":"Hardy M.","year":"2023","journal-title":"Research and Practice in Thrombosis and Hemostasis"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.thromres.2003.09.014","article-title":"Dextran Sulfate Included in Factor Xa Assay Reagent Overestimates Heparin Activity in Patients After Heparin Reversal by Protamine","volume":"111","author":"Mouton C.","year":"2003","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_50_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A Randomized Trial Comparing Activated Thromboplastin Time With Heparin Assay in Patients With Acute Venous Thromboembolism Requiring Large Daily Doses of Heparin","volume":"154","author":"Levine M. N.","year":"1994","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_8_51_1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1160\/TH06-05-0290","article-title":"Monitoring Unfractionated Heparin With the aPTT: Time for a Fresh Look","volume":"96","author":"Eikelboom J. W.","year":"2006","journal-title":"Thrombosis and Hemostasis"},{"key":"e_1_2_8_52_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.thromres.2017.07.006","article-title":"Should We Abandon the APTT for Monitoring Unfractionated Heparin?","volume":"157","author":"Arachillage D. R. J.","year":"2017","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_53_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1060028020961503","article-title":"Effectiveness of a Calculation\u2010Free Weight\u2010Based Unfractionated Heparin Nomogram With Anti\u2010Xa Level Monitoring Compared With Activated Partial Thromboplastin Time","volume":"55","author":"Kindelin N. M.","year":"2021","journal-title":"Annals of Pharmacotherapy"},{"key":"e_1_2_8_54_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.thromres.2021.10.010","article-title":"Comparison of Clinical Outcomes Using Activated Partial Thromboplastin Time Versus Antifactor\u2010Xa for Monitoring Therapeutic Unfractionated Heparin: A Systematic Review and Meta\u2010Analysis","volume":"208","author":"Swayngim R.","year":"2021","journal-title":"Thrombosis Research"},{"issue":"2","key":"e_1_2_8_55_1","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2146\/sp150016","article-title":"Comparison of Unfractionated Heparin Protocols Using Antifactor Xa Monitoring or Activated Partial Thrombin Time Monitoring","volume":"17","author":"Fruge K. S.","year":"2015","journal-title":"American Journal of Health\u2010System Pharmacy"},{"key":"e_1_2_8_56_1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1592\/phco.19.9.760.31547","article-title":"Monitoring Unfractionated Heparin Therapy With Antifactory Xa Activity Results in Fewer Monitoring Tests and Dosage Changes Than Monitoring With the Activated Partial Thromboplastin Time","volume":"19","author":"Rosborough T. K.","year":"1999","journal-title":"Pharmacotherapy"},{"key":"e_1_2_8_57_1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/1060028019835202","article-title":"Comparing Anti\u2010Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin","volume":"53","author":"Wahking R. A.","year":"2019","journal-title":"Annals of Pharmacotherapy"},{"key":"e_1_2_8_58_1","doi-asserted-by":"crossref","first-page":"108S","DOI":"10.1592\/phco.24.12.108S.36114","article-title":"Challenges in Variation and Responsiveness of Unfractionated Heparin","volume":"24","author":"Francis J. L.","year":"2004","journal-title":"Pharmacotherapy"},{"key":"e_1_2_8_59_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1309\/AJCPS6OW6DYNOGNH","article-title":"Activated Partial Thromboplastin Time and Anti\u2010Xa Measurements in Heparin Monitoring: Biochemical Basis for Discordance","volume":"139","author":"Takemoto C. M.","year":"2013","journal-title":"American Journal of Clinical Pathology"},{"key":"e_1_2_8_60_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.thromres.2019.01.002","article-title":"Agreement Between Activated Partial Thromboplastin Time and Anti\u2010Xa Activity in Critically Ill Patients Receiving Therapeutic Unfractionated Heparin","volume":"175","author":"Ratano D.","year":"2019","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_61_1","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1055\/s-0040-1719083","article-title":"Monitoring of Unfractionated Heparin in Severe COVID\u201019: An Observational Study of Patients on CRRT and ECMO","volume":"4","author":"Streng A. S.","year":"2020","journal-title":"TH Open"},{"key":"e_1_2_8_62_1","first-page":"170","volume-title":"Quality in Laboratory Hemostasis and Thrombosis","author":"Johnston M.","year":"2007"},{"key":"e_1_2_8_63_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.mbc.0000252595.79282.86","article-title":"Multicenter Evaluation of a Bilayer Polymer Blood Collection Tube for Coagulation Testing: Effect on Routine Hemostasis Test Results and on Plasma Levels of Coagulation Activation Markers","volume":"17","author":"Toulon P.","year":"2006","journal-title":"Blood Coagulation & Fibrinolysis"},{"key":"e_1_2_8_64_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.thromres.2005.11.005","article-title":"A New Plastic Collection Tube Made of Polyethylene Terephtalate Is Suitable for Monitoring Traditional Anticoagulant Therapy (Oral Anticoagulant, Unfractionated Heparin, and Low Molecular Weight Heparin)","volume":"119","author":"Toulon P.","year":"2007","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_65_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-3148.1999.00188.x","article-title":"Preanalytical Requirements for Flow Cytometric Evaluation of Platelet Activation: Choice of Anticoagulant","volume":"9","author":"Mody M.","year":"1999","journal-title":"Transfusion Medicine"},{"key":"e_1_2_8_66_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1042\/bj2090455","article-title":"Binding of Platelet Factor 4 to Heparin Oligosaccharides","volume":"209","author":"Denton J.","year":"1983","journal-title":"Biochemical Journal"},{"key":"e_1_2_8_67_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.1984.tb02936.x","article-title":"The Effect of Platelet Factor 4 (PF4) on Assays of Plasma Heparin","volume":"57","author":"Levine S. P.","year":"1984","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_68_1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0049-3848(83)90337-7","article-title":"Heparin Inactivation During Blood Storage: Its Prevention by Blood Collection in Citric Acid, Theophylline, Adenosine, Dipyridamole\u2010C.T.A.D. Mixture","volume":"31","author":"Contant G.","year":"1983","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_69_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11239-019-01882-1","article-title":"Is Citrate Theophylline Adenosine Dipyridamole (CTAD) Better Than Citrate to Survey Unfractionated Heparin Treatment? Has Delayed Centrifugation a Real Impact on This Survey?","volume":"48","author":"Billoir P.","year":"2019","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"e_1_2_8_70_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-023-00465-8","article-title":"Monitoring Heparin Therapy: Stability of Two Different Anti\u2010Xa Assays Using Blood Samples Collected in Citrate\u2010Containing and CTAD Tubes","volume":"21","author":"Gremillet M.","year":"2023","journal-title":"Thrombosis Journal"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20102749\u20106046"},{"key":"e_1_2_8_72_1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.thromres.2010.08.029","article-title":"Monitoring Treatments With Unfractionated Heparin: CTAD Must Be Used Instead of Citrate as the Anticoagulant Solution When Using Partial\u2010Draw Collection Tubes. Results of a Multicenter Evaluation","volume":"126","author":"Toulon P.","year":"2010","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_73_1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.thromres.2014.08.012","article-title":"Underestimation of Unfractionated Heparin Therapy Assessment due to Platelet Activation When Using Partial\u2010Draw (Pediatric) Citrate Collection Tubes","volume":"134","author":"Desconclois C.","year":"2014","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_74_1","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1515\/cclm-2024-0527","article-title":"The Final Part of the CRESS Trilogy \u2010 How to Evaluate the Quality of Stability Studies","volume":"62","author":"Cornes M.","year":"2024","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"e_1_2_8_75_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00001721-199809000-00002","article-title":"The Effect of Time and Temperature Variables on Routine Coagulation Tests","volume":"9","author":"Adcock D.","year":"1998","journal-title":"Blood Coagulation & Fibrinolysis"},{"key":"e_1_2_8_76_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2019.10.019","article-title":"Monitoring Unfractionated Heparin Therapy. 4 Hour\u2010Stability of Anti\u2010Xa Activity in Unspun Citrated Tubes","volume":"186","author":"Toulon P.","year":"2020","journal-title":"Thrombosis Research"},{"key":"e_1_2_8_77_1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1684\/abc.2025.1987","article-title":"Stability of Hemostatic Parameters in Whole Blood, Fresh Plasma, and Frozen Plasma: Literature Review and Recommendations From the French Society of Thrombosis and Hemostasis (SFTH)","volume":"83","author":"Flaujac C.","year":"2025","journal-title":"Annales de Biologie Clinique (Paris)"},{"key":"e_1_2_8_78_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the Practical Management of the Heparin Anticoagulants in the Treatment of Venous Thromboembolism","volume":"41","author":"Smythe M. A.","year":"2016","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"e_1_2_8_79_1","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1055\/a-2359-0987","article-title":"Management of Therapeutic\u2010Intensity Unfractionated Heparin: A Narrative Review on Critical Points","volume":"8","author":"Gouin\u2010Thibault I.","year":"2024","journal-title":"TH Open"},{"key":"e_1_2_8_80_1","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1515\/cclm-2020-0130","article-title":"Quality Performance for Indirect Xa Inhibitor Monitoring in Patients Using International External Quality Data","volume":"58","author":"Hollestelle M. J.","year":"2020","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20102779\u20100035"},{"key":"e_1_2_8_82_1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.296.8.935","article-title":"Comparison of Fixed\u2010Dose Weight\u2010Adjusted Unfractionated Heparin and Low\u2010Molecular\u2010Weight Heparin for Acute Treatment of Venous Thromboembolism","volume":"296","author":"Kearon C.","year":"2006","journal-title":"JAMA"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.70195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijlh.70195","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.70195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:55:07Z","timestamp":1784022907000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.70195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":81,"alternative-id":["10.1111\/ijlh.70195"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.70195","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"2026-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ijlh.70195"}}